Salvage chemotherapy in patients with nonsmall cell lung cancer after prior immunotherapy: a retrospective, real-life experience study

医学 化疗 免疫疗法 肺癌 回顾性队列研究 癌症 肿瘤科 挽救疗法 内科学 实体瘤疗效评价标准 性能状态 进行性疾病
作者
Ömer Diker,Polat Olgun
出处
期刊:Anti-Cancer Drugs [Lippincott Williams & Wilkins]
卷期号:33 (8): 752-757 被引量:1
标识
DOI:10.1097/cad.0000000000001330
摘要

Patients with advanced nonsmall cell lung cancer (NSCLC) who progress with immune checkpoint inhibitors (ICIs), salvage chemotherapy remains the only viable option for tumors that do not harbor genomic alterations. Data on the efficacy of salvage chemotherapy after immunotherapy (SCAI) are scarce. Our main objective in the current study was to evaluate the efficacy of SCAI. All consecutive patients who were diagnosed as having metastatic NSCLC and received at least one dose of ICIs were retrospectively reviewed. We computed progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) with SCAI. We also analyzed associations between survival and various clinicopathologic factors. We identified 35 patients with advanced NSCLC who received at least one dose of SCAI. The median age was 66 years. Most of patients were male ( n = 26, 74.3%) and former or current smokers ( n = 33, 94.3%). The majority of the patients were Eastern Cooperative Oncology Group Performance Status (ECOG PS) 2 ( n = 22; 62.9%), and there were no patients with driver mutations. SCAI was administered as second-line therapy in 21 (60.0%) patients and third-line in 14 (40.0%) patients. The ORR to SCAI was 20.0% with median PFS and OS were 2.43 (95% CI, 1.69–3.16) months and 4.40 (95% CI, 2.17–6.62) months, respectively. In multivariate analysis, ECOG PS 2 was confirmed as being independently associated with inferior OS. We demonstrated that patients with NSCLC who progressed to ICIs had limited clinical benefit with salvage chemotherapy, particularly for patients who were ECOG PS 2.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
简单的元珊完成签到,获得积分0
1秒前
wjl完成签到,获得积分10
1秒前
1秒前
歪歪关注了科研通微信公众号
1秒前
香香香发布了新的文献求助10
1秒前
2秒前
我是老大的应助被lxl采纳,获得10
2秒前
喜悦的秋柔完成签到,获得积分10
3秒前
明理小土豆完成签到,获得积分10
4秒前
彭于晏的应助被nicoleJ采纳,获得10
4秒前
无常完成签到,获得积分10
4秒前
HAOYUN驳回了Ava的应助
4秒前
4秒前
吃不饱发布了新的文献求助10
4秒前
4秒前
酷波er的应助被火星猎人采纳,获得10
6秒前
浅唱夏末发布了新的文献求助10
6秒前
黑米粥发布了新的文献求助200
6秒前
6秒前
FashionBoy的应助被尼克采纳,获得10
9秒前
9秒前
9秒前
Mhh发布了新的文献求助10
10秒前
10秒前
领导范儿的应助被dde采纳,获得10
10秒前
笑然发布了新的文献求助10
12秒前
982289172发布了新的文献求助10
12秒前
大宝宝完成签到 ,获得积分10
12秒前
13秒前
田様的应助被houyushen采纳,获得10
13秒前
13秒前
13秒前
dcc1234完成签到,获得积分10
13秒前
歪歪发布了新的文献求助10
15秒前
奋斗的凡完成签到,获得积分10
15秒前
16秒前
果果完成签到,获得积分10
16秒前
16秒前
16秒前
jie_e完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187572
求助须知:如何正确求助?哪些是违规求助? 9575676
关于积分的说明 21842241
捐赠科研通 7785368
什么是DOI,文献DOI怎么找? 3435022
关于科研通互助平台的介绍 2559428
邀请新用户注册赠送积分活动 2481917